ArQule To Present Data From Phase1/2 Trial Of ARQ 087

(RTTNews) - ArQule, Inc. (ARQL) Thursday said it plans to present the preliminary data from the ongoing phase 2 portion of a phase 1/2 trial in intrahepatic cholangiocarcinoma with proprietary fibroblast growth factor receptor inhibitor, ARQ 087 on June 30, 2016 at the ESMO World Congress.

The biomarker driven trial is designed to enroll at least 20 patients. The company has received orphan drug designation by FDA and European Medicine's Agency for ARQ 087 in this indication.

ArQule noted that Cholangiocarcinoma is the most common biliary malignancy and the second most common hepatic malignancy.